Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKLI Akili	$0.43	$0.43	$0.19 ▼ $1.25	$34.01M	1.72	2.20 million shs	N/A
LAKE Lakeland Industries	$13.35 -4.0%	$15.04	$12.76 ▼ $27.28	$132.35M	1.01	126,216 shs	108,701 shs
LUCD Lucid Diagnostics	$1.00 +2.2%	$1.20	$0.72 ▼ $1.80	$105.87M	1.21	984,937 shs	725,262 shs
LUNG Pulmonx	$1.61 -12.5%	$2.91	$1.59 ▼ $9.37	$74.07M	0.43	649,469 shs	1.87 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKLI Akili	0.00%	0.00%	0.00%	0.00%	0.00%
LAKE Lakeland Industries	-4.03%	-10.76%	-2.20%	-20.72%	-43.43%
LUCD Lucid Diagnostics	+2.19%	-9.91%	-4.76%	-22.18%	+25.39%
LUNG Pulmonx	-12.50%	-51.80%	-40.81%	-57.29%	-76.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKLI Akili	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LAKE Lakeland Industries	4.733 of 5 stars	3.5	1.0	0.8	4.9	2.6	3.3	2.5
LUCD Lucid Diagnostics	2.7079 of 5 stars	3.6	3.0	0.0	0.0	2.3	1.7	0.6
LUNG Pulmonx	3.855 of 5 stars	4.3	3.0	0.0	0.0	2.3	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKLI Akili	0.00	N/A	N/A	N/A
LAKE Lakeland Industries	3.00	Buy	$26.00	94.76% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	255.00% Upside
LUNG Pulmonx	2.56	Moderate Buy	$7.66	376.04% Upside

Current Analyst Ratings Breakdown

Latest AKLI, LAKE, LUNG, and LUCD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	LUNG Pulmonx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
7/31/2025	LUNG Pulmonx	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
7/31/2025	LUNG Pulmonx	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $5.00
7/31/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $16.00
7/31/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$9.00 ➝ $2.50
7/16/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/10/2025	LAKE Lakeland Industries	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKLI Akili	$1.95M	17.46	N/A	N/A	$0.75 per share	0.58
LAKE Lakeland Industries	$177.65M	0.72	$1.02 per share	13.03	$15.44 per share	0.86
LUCD Lucid Diagnostics	$4.35M	24.87	N/A	N/A	($0.78) per share	-1.28
LUNG Pulmonx	$83.79M	0.77	N/A	N/A	$2.17 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKLI Akili	-$59.49M	-$0.61	N/A	N/A	N/A	-2,492.04%	-79.93%	-59.16%	N/A
LAKE Lakeland Industries	-$18.08M	-$3.01	N/A	8.04	N/A	-13.31%	-6.88%	-4.47%	9/3/2025 (Estimated)
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/13/2025 (Estimated)
LUNG Pulmonx	-$56.39M	-$1.43	N/A	N/A	N/A	-62.88%	-66.36%	-35.51%	N/A

Latest AKLI, LAKE, LUNG, and LUCD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LUCD Lucid Diagnostics	-$0.09	N/A	N/A	N/A	$1.15 million	N/A
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	-$0.38	+$0.02	-$0.38	$23.46 million	$23.86 million
6/9/2025	Q1 2026	LAKE Lakeland Industries	$0.27	-$0.41	-$0.68	-$0.41	$48.84 million	$46.75 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKLI Akili	N/A	N/A	N/A	N/A	N/A
LAKE Lakeland Industries	$0.12	0.90%	N/A	N/A	1 Years
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKLI Akili	0.08	5.80	5.80
LAKE Lakeland Industries	0.17	3.88	1.51
LUCD Lucid Diagnostics	N/A	0.75	0.74
LUNG Pulmonx	0.38	4.97	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKLI Akili	53.12%
LAKE Lakeland Industries	71.69%
LUCD Lucid Diagnostics	74.01%
LUNG Pulmonx	91.04%

Insider Ownership

Company	Insider Ownership
AKLI Akili	10.10%
LAKE Lakeland Industries	1.91%
LUCD Lucid Diagnostics	6.80%
LUNG Pulmonx	6.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKLI Akili	130	78.73 million	70.78 million	Optionable
LAKE Lakeland Industries	2,100	9.52 million	9.33 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable

AKLI, LAKE, LUNG, and LUCD Headlines

Recent News About These Companies

Lake Street Capital Cuts Pulmonx (NASDAQ:LUNG) Price Target to $8.00

August 1 at 7:24 PM | marketbeat.com

Pulmonx Corporation (NASDAQ:LUNG) Q2 2025 Earnings Call Transcript

August 1 at 6:52 PM | msn.com

Stifel Nicolaus Cuts Pulmonx (NASDAQ:LUNG) Price Target to $5.00

August 1 at 1:05 PM | marketbeat.com

Pulmonx (NASDAQ:LUNG) Given New $16.00 Price Target at D. Boral Capital

August 1 at 9:32 AM | marketbeat.com

Pulmonx (NASDAQ:LUNG) Rating Lowered to "Neutral" at Piper Sandler

August 1 at 7:53 AM | marketbeat.com

Piper Sandler Downgrades Pulmonx (LUNG)

July 31 at 10:54 PM | msn.com

7LUNG : Analyst Expectations For Pulmonx's Future

July 31 at 5:54 PM | benzinga.com

Pulmonx slumps as Piper Sandler downgrades despite Q2 beat

July 31 at 5:54 PM | msn.com

Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of "Moderate Buy" by Brokerages

July 31 at 2:44 AM | americanbankingnews.com

Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by Brokerages

July 31 at 2:44 AM | marketbeat.com

Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript

July 30 at 11:02 PM | seekingalpha.com

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

July 30 at 7:01 PM | zacks.com

Pulmonx Reports Second Quarter 2025 Financial Results

July 30 at 4:05 PM | globenewswire.com

Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference

July 30 at 9:20 AM | manilatimes.netM

Essex Investment Management Co. LLC Makes New Investment in Pulmonx Corporation (NASDAQ:LUNG)

July 30 at 4:20 AM | marketbeat.com

Legato Capital Management LLC Takes $606,000 Position in Pulmonx Corporation (NASDAQ:LUNG)

July 25, 2025 | marketbeat.com

Pulmonx (LUNG) to Release Earnings on Wednesday

July 23, 2025 | marketbeat.com

Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025

July 16, 2025 | globenewswire.com

Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from Analysts

July 6, 2025 | marketbeat.com

Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 6, 2025 | marketbeat.com

Richard Ferrari Sells 8,000 Shares of Pulmonx Co. (NASDAQ:LUNG) Stock

June 14, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?
By Leo Miller | July 31, 2025
View Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?

AKLI, LAKE, LUNG, and LUCD Company Descriptions

Akili NASDAQ:AKLI

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Lakeland Industries NASDAQ:LAKE

$13.35 -0.56 (-4.03%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.36 +0.01 (+0.04%)

As of 08/1/2025 04:04 PM Eastern

Lakeland Industries, Inc. manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. It offers firefighting and heat protective apparel to protect against fire; high-end chemical protective suits to provide protection from highly concentrated, toxic and/or lethal chemicals, and biological toxins; and limited use/disposable protective clothing, such as coveralls, laboratory coats, shirts, pants, hoods, aprons, sleeves, arm guards, caps, and smocks. The company provides durable woven garments, including electrostatic dissipative apparel used in electronics clean rooms; flame resistant meta aramid, para aramid, and FR cotton coveralls/pants/jackets used in petrochemical, refining operations, and electrical utilities; FR fabrics; and cotton and polycotton coveralls, lab coats, pants, and shirts. In addition, it provides high visibility clothing comprising reflective apparel, including vests, T-shirts, sweatshirts, jackets, coats, raingear, jumpsuits, hats, and gloves; and gloves and sleeves that are used in the automotive, glass, and metal fabrication industries. The company sells its products to a network of safety and industrial supply distributors through in-house sales teams, customer service group, and independent sales representatives. It serves end users, such as integrated oil, chemical/petrochemical, automobile, steel, glass, construction, smelting, cleanroom, janitorial, pharmaceutical, and high technology electronics manufacturers, as well as scientific, medical laboratories, and the utilities industry; and federal, state, and local governmental agencies and departments. Lakeland Industries, Inc. was incorporated in 1982 and is headquartered in Huntsville, Alabama.

Lucid Diagnostics NASDAQ:LUCD

$1.00 +0.02 (+2.19%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.02 +0.02 (+2.50%)

As of 08/1/2025 07:55 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Pulmonx NASDAQ:LUNG

$1.61 -0.23 (-12.50%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.06 (+3.66%)

As of 08/1/2025 07:59 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time